The HPA axis and the genesis of chronic fatigue syndrome

被引:149
作者
Cleare, AJ [1 ]
机构
[1] Inst Psychiat, Sect Neurobiol Mood Disorders, Div Psychol Med, London SE5 8AF, England
关键词
D O I
10.1016/j.tem.2003.12.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many studies of patients with long-standing chronic fatigue syndrome (CFS) have found alterations to the hypothalamo-pituitary-adrenal (HPA) axis, including mild hypocortisolism, heightened negative feedback and blunted responses to challenge. However, recent prospective studies of high-risk cohorts suggest that there are no HPA axis changes present during the early stages of the genesis of fatiguing illnesses. Moreover, HPA axis changes can be reversed by modifying behavioural features of the illness, such as inactivity, deconditioning and sleep disturbance. Nevertheless, raising levels of cortisol pharmacologically can temporarily alleviate symptoms of fatigue. This article presents the case that there is no specific change to the HPA axis in CFS and that the observed changes are of multifactorial aetiology, with some factors occurring as a consequence of the illness. Nevertheless, the HPA axis might play a role in exacerbating or perpetuating symptoms late on in the course of the illness.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 34 条
[1]  
Abelson JL, 1996, ARCH GEN PSYCHIAT, V53, P323
[2]  
[Anonymous], 1998, Chronic fatigue and its syndromes
[3]   Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: A randomized, placebo-contriolled, double-blind, crossover study [J].
Blockmans, D ;
Persoons, P ;
Van Houdenhove, B ;
Lejeune, M ;
Bobbaers, H .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (09) :736-741
[4]   Predictors of fatigue following the onset of infectious mononucleosis [J].
Candy, B ;
Chalder, T ;
Cleare, AJ ;
Peakman, A ;
Skowera, A ;
Wessely, S ;
Weinman, J ;
Zuckerman, M ;
Hotopf, M .
PSYCHOLOGICAL MEDICINE, 2003, 33 (05) :847-855
[5]  
Cleare A J, 2001, Adv Psychosom Med, V22, P17
[6]   Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial [J].
Cleare, AJ ;
Heap, E ;
Malhi, GS ;
Wessely, S ;
O'Keane, V ;
Miell, J .
LANCET, 1999, 353 (9151) :455-458
[7]   The neuroendocrinology of chronic fatigue syndrome [J].
Cleare, AJ .
ENDOCRINE REVIEWS, 2003, 24 (02) :236-252
[8]   Plasma leptin in chronic fatigue syndrome and a placebo-controlled study of the effects of low-dose hydrocortisone on leptin secretion [J].
Cleare, AJ ;
O'Keane, V ;
Miell, J .
CLINICAL ENDOCRINOLOGY, 2001, 55 (01) :113-119
[9]   Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy [J].
Cleare, AJ ;
Miell, J ;
Heap, E ;
Sookdeo, S ;
Young, L ;
Malhi, GS ;
O'Keane, V .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08) :3545-3554
[10]  
CLEARE AJ, 2003, END ABSTR, V5, pS35